Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients

Lonapegsomatropin, a long-acting GH therapy (LAGH), was approved by the United States Food and Drug Administration in August 2021 for the treatment of pediatric growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug consisting of unmodified GH transiently conjugated to methoxypolyethylene g...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Bradley S, Yuen, Kevin C J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250779/
https://www.ncbi.nlm.nih.gov/pubmed/35791404
http://dx.doi.org/10.2147/DDDT.S336285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250779/
https://www.ncbi.nlm.nih.gov/pubmed/35791404
http://dx.doi.org/10.2147/DDDT.S336285

Ejemplares similares